不同用药方法对盖诺临床疗效及不良反应的影响  

To evaluate the efficacy and adverse reactions of different drugs for Gainor in malignant tumor

作　　者：陈伟荣[1] 杨权烈[1] 张锦宏[1] 

机构地区：[1]广东省梅州市人民医院,广东梅州514031

出　　处：《中国民族民间医药》2015年第13期55-55,57,共2页Chinese Journal of Ethnomedicine and Ethnopharmacy

摘　　要：目的:观察盖诺不同用药方法在部分恶性肿瘤治疗中的疗效和不良反应。方法:以136例恶性肿瘤患者为研究对象,根据盖诺用药方法分成两组,A组(68例)连续静脉滴注,盖诺10mg先静脉推注,然后10mg静脉滴注,连续用药5d,总剂量60mg;B组(68例)快速静滴,盖诺40mg于第1天和第8天静脉滴注,两组同时联合顺铂治疗,3周1疗程,两疗程后比较两组临床疗效和不良反应。结果:两疗程后两组总有效率及用药过程中骨髓抑制、消化道反应、周围神经炎、静脉炎发生率比较差异均无统计学意义(P>0.05)。结论:连续静脉滴注和快速静脉滴注两种盖诺用药方法的疗效和安全性相当。Objective To study the curative effect and adverse reaction of different medication methods in treatment of part of malignant tumors. Methods 136 cases of patients with malignant tumors treated in our hospital were selected as the research object and were divided into two groups according to the Gainor administration method. 68 cases of the patients in group A were given continuous intravenous drip infusion, （first vinorelbine 10mg intravenous injection, and then vinorelbine 10mg intravenous drip infusion）. The continuous administration lasted five days and the total dose was 60mg. 68 cases of the patients in group B were given rapid intravenous drip. The first and eighth day of intravenous infusion was vinorelbine 40mg. The patients in two groups were treated combined with cisplatin and 3 weeks was 1 period of treatment. The clinical efficacy and adverse reactions in the patients in two groups were compared after two courses of treatment. Results After 2 courses of treatment, there was no statistically significant difference in total effective rate between groups （ P 〉 0. 05 ）. In the process of treatment, bone marrow inhibition, gastrointestinal reactions, peripheral neuritis and the incidence of phlebitis was no statistically significant difference in efficacy between groups （ P 〉 0. 05 ）. Conclusion The efficacy and safety of the vinorelbine administration method of continuous intravenous drip infusion and rapid intravenous drip are considerable.

关 键 词：用药方法 盖诺 临床疗效 不良反应 

分 类 号：R969.3[医药卫生—药理学]